Bartels H, Fenner A, van der Merwe W, Barbalatt S, Wolfsdorf J
Eur J Pediatr. 1977 Jun 1;125(2):97-102. doi: 10.1007/BF00489983.
Sixty-seven babies were utilized to (a) document the serum bilirubin lowering effect and safety of a phenobarbitone and nikethamide combination in neonatal hyperbilirubinaemia of non-hemolytic origin; (b) determine whether birthweight and/or SGOT, SGPT or SGGT activity on day one of life correlated with the maximum serum bilirubin level achieved; and (c) investigate the pattern of hepatic enzyme levels in serum under normal conditions anf following drug induction. Results indicate a significantly lower serum bilirubin level in the treated group of babies. Birthweight and day one SGGT levels, and SGGT/birthweight ratio correlated well with the maximum serum bilirubin reached, the latter ratio being particularly useful in predicting the degree of hyperbilirubinaemia.
67名婴儿被用于:(a) 记录苯巴比妥和尼可刹米联合用药对非溶血性新生儿高胆红素血症的血清胆红素降低作用及安全性;(b) 确定出生体重和/或出生第一天的谷草转氨酶(SGOT)、谷丙转氨酶(SGPT)或γ-谷氨酰转肽酶(SGGT)活性与达到的最高血清胆红素水平是否相关;(c) 研究正常情况下及药物诱导后血清中肝酶水平的变化模式。结果表明,治疗组婴儿的血清胆红素水平显著降低。出生体重和出生第一天的SGGT水平以及SGGT/出生体重比值与达到的最高血清胆红素密切相关,后一比值在预测高胆红素血症程度方面特别有用。